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Abstract
HPV testing compared with routine cytology in cervical
screening: long-term follow-up of ARTISTIC RCT
Clare Gilham,1 Alexandra Sargent,2 Henry C Kitchener3
and Julian Peto1*
1Non-Communicable Disease Epidemiology Unit, London School of Hygiene & Tropical Medicine,
London, UK
2Department of Virology, Central Manchester University Hospitals NHS Foundation Trust,
Manchester, UK
3School of Cancer and Sciences, University of Manchester, St Mary’s Hospital, Manchester, UK
*Corresponding author julian.peto@lshtm.ac.uk
Background: The National Screening Committee (NSC) based its recommendation that human
papillomavirus (HPV) testing should replace cytology in primary cervical screening largely on the 2009
follow-up results of the ARTISTIC trial (A Randomised Trial In Screening To Improve Cytology). The NSC
must now decide on screening intervals and triage policy. Options include extending the screening
interval up to 10 years for human papillomavirus-negative (HPV–) women, delaying recall for human
papillomavirus-positive (HPV+) women with normal cytology (as their infections are usually transient),
and basing triage on full HPV typing.
Methods: In ARTISTIC, 24,510 women were recruited who were attending routine cervical cytology in
Greater Manchester in 2001–3. The women were randomly allocated between revealing and concealing
their HPV test results and were recalled every 3 years. After 2009, the women returned to routine
cytological screening with recall every 3 years for those aged < 50 years, and every 5 years for those
aged 50–64 years. We have followed the cohort to 2015 through national cancer registration for CIN3
(cervical intraepithelial neoplasia grade 3) and cancer, and through linkage to the cervical screening
call–recall system to obtain lifetime cytology records.
Results: The analysis comprised 24,496 women at round 1 and 13,591 women at round 2 (which was
30–48 months later). Follow-up via local histology laboratories and national cancer registration identified
505 cases of cervical intraepithelial neoplasia grade 3 or cervical cancer (CIN3+) (including 22 invasive
cervical cancers). The cumulative CIN3+ risk 10 years after a negative HPV test [0.31%, 95% confidence
interval (CI) 0.18% to 0.49%, in the revealed arm] was similar to that 3 years after negative cytology
(0.30%, 95% CI 0.23% to 0.41%, in the concealed arm) and fell sharply with age, from 1.1% (95% CI
0.7% to 1.8%) in those women aged < 25 years to 0.08% (95% CI 0.03% to 0.20%) in those women
aged > 50 years. The 10-year cumulative CIN3+ risk following a new HPV infection at round 2 was 3.4%
(95% CI 2.1% to 5.4%). The highest risks were associated with type-specific persistent infections that,
overall, resulted in a 10-year cumulative CIN3+ risk of 20.4% (95% CI 15.6% to 26.4%).
Conclusions: We found a similar level of protection 10 years after a negative HPV test and 3 years after
negative cytology. These data support a considerably longer screening interval after a negative HPV test
than after a negative cytology test. About three-quarters of women with HPV infection and normal
cytology clear their infections within about 3 years. Their risk of CIN3+ within this time frame is low (1.5%),
suggesting that the current policy of annual repeat testing and referral after 2 years may be unnecessarily
cautious. Approximately 40% of women who remained HPV+ had cleared their initial infection and acquired
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a new HPV type. The cumulative CIN3+ risks in women with type-specific persistent infections are about
six times higher than in women with new infections. Triage strategies based on HPV persistence would,
therefore, reduce unnecessary referral of women with new (and largely transient) infections. HPV assays
that identify HPV types 31, 33, 45, 52 and 58 in addition to 16 and 18 could be useful in triage as well
as in primary HPV testing. Similar results in recent routine HPV screening suggest that our results are
generalisable despite changes in cytology and HPV assay methods. We are continuing to follow the
ARTISTIC cohort into the new era of primary HPV screening. Future work will focus on the implications of
more sensitive HPV testing for primary HPV screening policy and triage of HPV-positive women. Our results
suggest that a more sensitive test is needed to detect occult CIN3 at high risk of progression to cancer, but
this would substantially increase the overall HPV detection rate. Tests such as DNA (deoxyribonucleic acid)
methylation for distinguishing HPV infection from neoplasia will be evaluated on stored samples and on
further samples now being collected from women in the cohort who are still being screened.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 28.
See the NIHR Journals Library website for further project information.
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Plain English summary
Human papillomavirus (HPV) causes cervical cancer. The latest scientific evidence shows that screeningfor HPV is better than screening for abnormal cytology with a ‘smear’ test, so HPV testing is being
rolled out nationally. The main disadvantage is that more women will test positive and be referred for
further tests. Most infections are harmless and clear without treatment, and balance must be achieved so
that women who progress to CIN3 (pre-cancer) are identified but that unnecessary referral and anxiety for
women is minimised.
A Randomised Trial In Screening To Improve Cytology (ARTISTIC) recruited 24,510 women attending for
cervical screening in Greater Manchester in 2001–3. Cervical samples taken at recruitment and again at
screening 3 and 6 years later were tested for HPV. The women then returned to routine screening. We
have followed them through national screening records and cancer registration until the end of 2015.
By comparing the HPV results taken at entry with those collected 3 years later, we can categorise HPV
infections into new and persistent. We have found that the CIN3 risk in women with persistent infections
is about six times higher than in women with new infections, which in turn is about 30 times higher than
in women with no infection.
About three-quarters of women with HPV infection but no abnormal cells clear their infections within
3 years. Their risk of pre-cancer within 3 years is low (1.5%) and so intensive follow-up is unnecessary.
Moreover, 40% of those who remain human papillomavirus positive (HPV+) have cleared their initial
infection and acquired a new infection, meaning that they are also at much lower risk of disease than
those with a persistent infection. The current practice in the national pilot study of annual repeat testing
and referral of anyone who is still HPV+ after 2 years may, therefore, be too conservative.
We have also shown that the CIN3 risk after 10 years in women testing negative for HPV is similar to the
risk after about 3 years in women testing negative for cytology. This means that screening intervals could
be extended for women testing negative for HPV.
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Scientific summary
Background
The National Screening Committee (NSC) based its recommendation that human papillomavirus (HPV)
testing should replace cytology in primary cervical screening largely on the 2009 follow-up results of A
Randomised Trial In Screening To Improve Cytology (ARTISTIC) [URL: https://legacyscreening.phe.org.uk/
cervicalcancer (accessed 19 April 2018)]. The NSC must now decide on screening intervals in time for
national roll-out of primary HPV screening, currently scheduled for December 2019. Options include
extending the screening interval for up to 10 years for human papillomavirus-negative (HPV–) women
and delaying recall for human papillomavirus-positive (HPV+) women by up to 3 years if their cytology is
normal, and perhaps by only 1 year if their cytology is borderline or mild. HPV infections are usually
transient and a substantial reduction in triage costs and procedures could be achieved if a longer delay
in patient recall was shown to be safe.
Methods
In ARTISTIC, 24,510 women attending for routine cervical cytology in Greater Manchester were recruited
between 2001 and 2003. Cytology was conducted as part of the national screening programme using
liquid-based cytology (LBC) technology and women with abnormal cytology were managed under national
guidelines, irrespective of HPV results. Women were recalled twice, 3 and 6 years after entry. LBC samples at
entry and at rounds 2 and 3 were tested for HPV and the residual material stored. Women were randomly
allocated to reveal or conceal their HPV test results, and on the revealed arm women with normal cytology
who were HPV positive were recalled after 1 year for a repeat HPV test. Histology results were obtained from
local laboratories. After 2009, follow-up and sample collection ended and the women returned to routine
cytological screening with recall every 3 years for those aged < 50 years and every 5 years for those aged
50–64 years. We have followed the trial cohort through national cancer registration for cervical intraepithelial
neoplasia grade 3 (CIN3) and cancer, and through linkage to the cervical screening call–recall system for
lifetime cytology records. Cumulative cervical intraepithelial neoplasia grade 3 or cervical cancer (CIN3+) risks
were calculated comparing women according to HPV and cytology status at baseline. Additional analyses
began at round 2, when persistent and newly acquired infections could be distinguished and the high
prevalence of accumulated CIN3 missed by earlier screening had been eliminated at entry.
Results
The analysis comprised 24,496 women at round 1 and 13,591 women at round 2 (defined as the first test
30–48 months later). Follow-up was via local histology laboratories until 2009 when the trial ended and
then via cancer registration until April 2015. This identified 505 cases of CIN3+ (including 22 invasive
cancers). Similar cumulative CIN3+ risks were seen 10 years after a negative hybrid capture 2 (HC2) test
at entry [0.31%, 95% confidence interval (CI) 0.18% to 0.49%, in the revealed arm] and 3 years after a
negative cytology test at entry (0.30%, 95% CI 0.23% to 0.41%, in the concealed arm). The 10-year
cumulative CIN3+ risk in women who were hybrid capture 2 negative (HC2–) at entry was highest in
women aged 20–24 years (1.10%, 95% CI 0.69% to 1.77%) and significantly higher (p < 0.001) in
women aged 25–39 years (0.40%, 95% CI 0.28% to 0.56%) than in those aged > 40 years (0.11%,
95% CI 0.06% to 0.20%).
The availability of partial or full HPV genotyping assays allows risk-based stratification in an organised screening
programme. Four out of the six sites in the UK pilot study are utilising partial typing HPV tests [Roche
COBAS (Roche Molecular Diagnostics, Pleasanton, CA, USA) and Abbott Realtime Assays (Abbott Molecular,
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Maidenhead, UK)] that identify HPV 16 and HPV 18 infections. We found a much higher cumulative CIN3+
risk among women with HPV 16 infection than among women with any other genotype. Although HPV 16
constituted 22% of all hybrid capture 2-positive (HC2+) infections, 57% of CIN3+ occurred among this group
of women, giving a 10-year cumulative CIN3+ risk of 29.8% (95% CI 26.8% to 33.0%). HPV 18 constituted
9% of all HC2+ infections (including 2% who also had HPV 16), with a 10-year cumulative CIN3+ risk similar
to the group of high-risk HPV types comprising 31, 33, 45, 52 and 58.
The 10-year cumulative CIN3+ risk following a new high-risk HPV (HRHPV) infection at round 2 was low
(3.4%, 95% CI 2.1% to 5.4%). HPV 16 again showed the highest 10-year risk following a new infection
(7.3%, 95% CI 3.7% to 14.1%), suggesting that women with HPV 16 might be referred immediately.
Much higher risks were associated with any type-specific persistence (the same HPV type as in round 1),
which overall conferred a 10-year cumulative risk of 20.4% (95% CI 15.6% to 26.4%). The cumulative
CIN3+ risk following type-specific persisting infection was similar regardless of age before the age of
40 years (23.8%, 95% CI 18.2% to 30.9%), but significantly lower (p = 0.02) in women aged ≥ 40 years
(6.8%, 95% CI 2.3% to 19.7%). Persistent HPV 16 infections account for 44% of type-specific infections
in those aged < 30 years and only 11% among women aged ≥ 40 years, but stratification by type does
not entirely account for the reduction in CIN3+ risk in women aged ≥ 40 years. Of the 331 women
with double positive HRHPV tests, 115 (35%) were positive with a new HPV type at the second test and
216 (65%) were type-specific persistent. The proportion with new infections was highest in younger
women (43% in women in their 20s) and decreased to 23% of double positive infections in women
aged ≥ 50 years. Entry samples for 17 out of the 23 cervical cancers diagnosed so far (including one
diagnosed after the follow-up date) were HC2+. Five of the 6 HC2– entry samples were found to be
HPV+ on retesting by PCR.
Conclusions
The CIN3+ risk 10 years after a negative HPV test is similar to that at 3 years after a negative cytology test.
The risk at each age is approximately proportional to the incidence of new HPV infection in the population,
which falls sharply with age and is very low in those aged ≥ 40 years. These data support a longer
screening interval after a negative HPV test than after a negative cytology test. This could be at least
5 years, and might be extended to 10 years for women aged ≥ 50 years, or perhaps aged ≥ 40 years.
About three-quarters of women with HPV infection and normal cytology clear their infections within 3
years. Their risk of CIN3+ within this time is low (1.5%), suggesting that the protocol in the national pilot
of annual repeat testing [Public Health England. HPV Primary Screening Pilot Protocol Algorithm. Version
3.0. Public Health England; 2016. URL: https://assets.publishing.service.gov.uk/government/uploads/system/
uploads/attachment_data/file/529496/HPVPSFlowchart-Version3_Jan16.CURRENTppt.pdf (accessed
19 April 2018)] and referral after 2 years may be too conservative. Approximately 40% of women who
remained high-risk HPV+ at round 2 had cleared their initial infection and acquired a different HPV type.
They had less than 20% of the CIN3+ risk of those with type-specific persistence. Women with HPV 16 or
HPV 18 and normal cytology are being referred to immediate colposcopy in some centres in the national
pilot. Strategies based on full or partial HPV typing could be considered in triage as well as in primary HPV
screening. Future work will focus on the implications of more sensitive HPV testing for primary HPV
screening policy and triage of HPV-positive women. Our results suggest that a more sensitive test is
needed to detect occult CIN3 at high risk of progression to cancer, but this would substantially increase
the overall HPV detection rate. Tests such as DNA methylation for distinguishing HPV infection from
neoplasia will be evaluated on stored samples and on further samples now being collected from women in
the cohort who are still being screened.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
The NHS Cervical Screening Programme is already one of the most successful in the world in preventingcervical cancer,1,2 but unnecessary referral and treatment should be minimised to reduce NHS costs,
inconvenience to women and unnecessary treatment for low-grade cervical dysplasia, which can
compromise later birth outcomes. Human papillomavirus (HPV) testing is already used in the UK
to triage borderline and mild cervical cytology and as a test of cure following excision of cervical
intraepithelial neoplasia (CIN). National roll-out of primary HPV testing, scheduled to be complete by
December 2019, will further increase sensitivity; however, referrals and, hence, costs will also increase
without longer screening intervals and more efficient triage methods for human papillomavirus-positive
(HPV+) women. Primary HPV testing with cytology triage of HPV+ women is being piloted at several sites
in England following publication of ARTISTIC trial (A Randomised Trial In Screening To Improve Cytology)
results over three rounds of HPV screening3–5 and pooled data from ARTISTIC and other randomised trials
showing a reduction in long-term cervical cancer risk.6 The aim of primary HPV screening is to reduce
cervical cancer risk by identifying women with high-grade CIN early enough to prevent progression to
invasive cancer. The introduction of primary HPV testing in the NHS Cervical Screening Programme will
require practical decisions on screening intervals for different age ranges as well as the triage protocol for
HPV+ women. The results up to 2009 from the initial screening rounds in ARTISTIC contributed to the
decision to pilot HPV primary screening,7 and this extension to 2015 gave a 10-year follow-up from entry,
providing further evidence to optimise screening protocols.
The CIN grade 3 or cervical cancer (CIN3+) rate in the second round of ARTISTIC was less than half the rate
at entry, as the majority of cases diagnosed at entry reflected a long-term accumulation missed by previous
screening.5 Virtually all prevalent cases will be detected when HPV screening is first introduced. Therefore,
follow-up from round 1 represents what will be seen when primary HPV screening is introduced, while
follow-up from round 2 represents what will be seen at the second and subsequent rounds of HPV screening.
For the purpose of modelling an established HPV screening programme, an important group are the 85% of
women who were human papillomavirus negative (HPV–) at entry (round 1), as long follow-up of those with
new infections detected at round 2 represents the time course of HPV persistence and CIN3+ risk following
first infection. Extending follow-up to 2015 has increased the median follow-up beyond round 2 in ARTISTIC
from 4 to 10 years.
Follow-up of the cohort to 2009 showed that the subsequent CIN3+ rate is substantially lower following a
single negative HPV test than for negative cytology,4 and this was influential in the National Screening
Committee’s (NSC’s) recommendation that HPV testing should replace cytology as the primary screening
test. This further follow-up beginning at round 2 will show whether or not the screening interval can safely
be increased from the current routine (3 years for those aged < 50 years and 5 years for those aged
≥ 50 years) to up to 10 years for HPV– women, irrespective of previous test results.
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Chapter 2 Objectives
The objective of this extended follow-up of the ARTISTIC cohort was to obtain the data required toevaluate the long-term benefits of alternative screening strategies using primary HPV testing, including
the following:
1. The long-term cumulative CIN3+ risk following a negative HPV test, and, hence, the safe screening
interval at different ages.
2. The effect of HPV type on CIN3+ risk following a positive HPV test, and, hence, the role of HPV
genotyping in routine screening.
3. The difference in CIN3+ risks following round 2 between women with type-specific HPV persistence
since round 1 and those with a newly acquired HPV type. This is relevant to the triage protocol for
HPV+ women: the interval to retesting, and either referral for colposcopic examination or further
testing in women who remain HPV+ based on HPV typing and cytology.
4. The effects on CIN3+ risk of different ages at starting and stopping screening. The high prevalence of
CIN2+ at age 20–24 years (6.3%) in round 1 of ARTISTIC4 showed that many cases detected when
women are first screened at age 25 years developed more than 5 years earlier. The long-term CIN3 risk
in HPV– women who are aged ≥ 50 years is very low, but if they are never screened again their lifetime
then cancer risk may not be negligible.
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Chapter 3 Methods
Data collection during the trial (2001–9)
ARTISTIC compared cytology with and without HPV testing among 24,510 women attending routine
cervical screening in 2001–3. Over 60,000 HPV tests [hybrid capture 2 (HC2) with full HPV typing of those
testing positive] were performed on routinely collected liquid-based cytology (LBC) cervical samples until
September 2009. Methods are described elsewhere3,5 reporting that women were randomly allocated in a
ratio of 1 : 3 between having their HPV results concealed (concealed arm, n = 6124) or revealed (revealed
arm, n = 18,386). All women with abnormal cytology were recalled for retesting or referred to colposcopy
according to national guidelines.3 After March 2008, the laboratory became part of the Sentinel Sites
project in which low-grade cytological abnormalities were triaged using HPV. Women were referred with
borderline or mild cytology only if they tested positive for HPV; otherwise, they were returned to routine
recall. In addition, women in the revealed arm with normal cytology who were hybrid capture 2 positive
(HC2+) were recalled for repeat HPV testing, and those whose HPV infection persisted were referred
to colposcopy.
Liquid-based cytology was carried out using ThinPrep® (Hologic, Crawley, UK) and HPV testing using HC2
(Qiagen, Crawley, UK). A cut-off point of 1 relative light unit/mean control (RLU/Co) pg/µl was used to
identify positive HPV samples, which were genotyped using at least one of three HPV typing assays.
All HC2+ samples during rounds 1 and 2 were genotyped using the prototype Roche Line Blot Assay (Roche
Molecular Diagnostics, Pleasanton, CA, USA).3 This was replaced by the commercially available Linear Array
assay and the PapilloCheck® assay (Greiner Bio-one GmbH, Frickenhausen, Germany) during round 3. In
addition, approximately two-thirds of archived HC2+ round 1 samples were also tested by the PapilloCheck
assay and one-third of archived HC2+ round 2 samples were tested by the Roche Linear Array®. In all
three rounds, any of the 13 high-risk human papillomavirus (HRHPV) types detected by HC2 (HPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) that was detected by any of the assays was included in the
analysis. All other HPV types were ignored in all analyses.
After the trial ended in 2009, all women returned to routine cytology every 3 years if they were aged
< 50 years, and every 5 years if they were aged 50–64 years. We have published reports on baseline
data,8,9 follow-up through two further screening rounds3–5,10 and various other HPV-related issues.6,11–13
These analyses were based on follow-up to 2009 through two cytology laboratories in the Manchester
area. Any women moving out of the area were lost, and only 60% of the ARTISTIC cohort had a cytology
record between 2006 and 2009.
Further data collection (2010–16)
NHS Central Register for cancer incidence and mortality
The cohort was flagged through NHS Central Register (NHSCR), giving notification of deaths and cancer
diagnoses, including carcinoma in situ of the cervix (CIN3), until December 2015.
National screening programme call–recall cytology and human papillomavirus records
The cohort was linked to the NHS Cervical Screening Programme call–recall database to obtain lifetime
cervical screening records for the entire ARTISTIC cohort. This included any recorded HPV results taken
after triaging of borderline or mild dyskaryosis cytology or as part of primary HPV screening (in pilot areas).
The reasons for ceasing screening, including hysterectomy, were also recorded.
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Testing stored samples for human papillomavirus deoxyribonucleic acid
All samples taken during the trial have been tested using HC2 with HPV typing for HC2+ samples. Women
who consented to their HPV samples being retained for future research are now stored at Professor Lorincz’s
laboratory at QMUL. Sensitive polymerase chain reaction (PCR)-based assays [Roche Line Blot assay and
PapType® assay (Genera Biosystems, Scoresby, VA, Australia)] were carried out on hybrid capture 2-negative
(HC2–) samples from women who have developed invasive cervical cancer since 2009.
METHODS
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Chapter 4 Definitions and statistical methods
Definition of round 2 follow-up
In previous reports, round 2 was defined as the first adequate cytology between 26 and 54 months after
entry, which included 10% with no adequate HPV test on their round 2 sample. In this report, round 2
is defined as the first adequate HPV test between 30 and 48 months after entry. Under this definition,
13,591 women had a round 2 test, on average, 3 years and 7 months after entry. In analyses beginning at
round 2, 185 women with CIN3+ registration/histology before this date and six women whose flagging
data indicated that they had cancelled from the NHSCR before this date were excluded.
Human papillomavirus clearance
To estimate and compare clearance rates of recently acquired and long-standing HPV infections (i.e. those
already present at entry), clearance from the second HPV test in ARTISTIC (regardless of time since entry)
was assessed. Women with any histology, regardless of result, between the second and third HPV tests
were excluded in case the action of taking a biopsy affected the clearance rate. In addition, women with
CIN3+ histology before the second HPV test were excluded. A total of 1026 women with at least three
HPV tests whose second test was positive for HRHPV were included in the analysis. Each infection with a
HPV type was considered independently, so women with more than one HPV type were counted more
than once in the analysis. Clearance of each infection was calculated by time between the second and
third HPV test and stratified by whether or not the same HPV type was present at entry (i.e. whether the
infection developed since entry or was prevalent at entry).
Human papillomavirus recurrence
The recurrence of type-specific HPV infections was counted in women who had HRHPV infections at round
1 and subsequently tested HC2–. The time to ‘clearance’ (defined as testing HC2–) was stratified into
‘short term’, defined as clearance of < 24 months after round 1, and ‘long term’, defined as clearance
24–54 months after round 1. Recurrence in these two groups of women was defined as any subsequent
HRHPV+ result with one or more genotype identified that was also present at entry. Under the protocol,
genotyping was not carried out on HC2– samples, which implies that ‘clearance’ means that the HPV
infection had become undetectable by HC2.
Type-specific human papillomavirus persistence
The HPV types found in round 2 (30–48 months after entry) were compared with those identified in round 1
so that round 2 infections could be classified as new or persistent. Women with a type-specific persistent
infection with or without a new infection of a different genotype were classified as persistent.
Human papillomavirus status
In most other analyses, women were classified hierarchically into mutually exclusive groups: HPV 16 or
HPV 18, any of HPV types 31, 33, 45, 52 or 58 (without 16 or 18), any other HRHPV, HC2+ with no HRHPV,
or HC2–.
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Calculation of cumulative risk for cervical intraepithelial neoplasia or
cervical cancer
Cumulative CIN3+ risks were estimated by Kaplan–Meier methods. Subgroups were compared using the
log-rank test. Cumulative risks were calculated from entry (round 1) and also from round 2 when incident
and persistent infections could be distinguished. Women were censored at date of last cytology prior to
hysterectomy according to call–recall data. All analyses were censored on 30 April 2015 to allow for late
registration of CIN3 and cancer.
Kaplan–Meier analysis of interval-censored data
The aim of the cumulative risk analyses is to estimate the probability that CIN3+ would be detected by a
test at a given time after entry to follow-up, beginning either at entry to the trial or at round 2. This raises
several issues.
1. We ignore the possibility that CIN3 occasionally regresses, so cumulative risks may overestimate the
prevalence that would be observed if the next test were 5 or 10 years later.
2. CIN3+ histology is backdated to the beginning of follow-up if the histology/registration occurred
within a year of the beginning of follow-up. These cases are shown at time zero giving an initial step
in the Kaplan–Meier curve. Some of these cases were not present at the time of the initial abnormal
cytology or positive HPV test but developed during the period of repeat testing.
3. Later CIN3+ histology/registration dates are backdated to the first test in the preceding year, then
further backdated to the mid-point of the interval between that test and the preceding test. For three
cancers and a single CIN3 lesion with no recorded cytology within a year, the histology date is taken as
the end of the interval. One further cancer was censored on ceasing screening and thus excluded.
This modified Kaplan–Meier treatment of interval-censored data, in which lesions are assigned to the
mid-point of the screening interval where they became detectable, gives results similar to a parametric
analysis (Professor Peter Sasieni, Queen Mary University of London, 2017, personal communication).
The second-order error is that the interval mid-point is not the expected value of the time when the CIN3
would be detectable, which may be slightly earlier or later depending on the assumed model of HPV
acquisition and CIN3 development.
DEFINITIONS AND STATISTICAL METHODS
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Chapter 5 Results
Section 1: description of data
Eligible data
The cohort that participated in ARTISTIC consisted of 24,510 women aged between 20 and 64 years and
provided an adequate cytology and HPV test at enrolment. Fourteen women did not have a valid NHS
number and so 24,496 women were flagged with NHS Digital for cancer registration and death. These
women were then linked to the National Screening Programme call–recall system, which yielded a final
cohort of 23,888 after excluding three non-matches and 605 type-2 opt-outs (those opting out of their
data being accessed for medical research) (Figure 1). The call–recall data were linked by NHS number to
ensure correct linkage. At least one cytology date and result from the laboratory database matched the
call–recall data in all but 53 women (99.8%). These 53 women were individually examined and most had
only one or two tests identified through the laboratory. We assumed that these cytology dates had not
been recorded correctly on the call–recall system. For those whose call–recall screening records matched
the Manchester laboratory data during the trial (2001–9), it was not uncommon for some records to be
inconsistent between the systems.
Follow-up via local histology laboratories to 2009 when the trial ended and via cancer registrations to
April 2015 identified 509 cases of CIN3+, including 23 invasive cancers. Three cases of CIN3 were excluded
owing to censoring at last cytology as no link was made to call–recall data. In addition, one invasive cancer
was excluded as the woman’s screening record indicated that she had ceased screening after reaching the
age of 65 years. Therefore, 505 cases of CIN3+ were included in the analysis (Table 1).
Women enrolled 2001–4 randomised 3 : 1
 between HPV result revealed or concealed 
and followed through local laboratories 
until 2009
 (n =  24,510) 
Flagged for cancer incidence and matched
to call–recall data for cytology screening
records (followed up until April 2015)
 (n =  23,888) 
Non-matches
(n =  3) 
Type-2 patient objections 
(censored at trial exit)
(n =  605) 
Submitted for matching to 
call–recall records 
Women untraced
(n =  14) 
ARTISTIC cohort
Women flagged for CIN3, cancer registrations 
and mortality
(n =  24,496) 
FIGURE 1 The CONSORT (Consolidated Standards of Reporting Trials) flow of diagram showing women followed
up for cancer registration and mortality through national registration, and for cytology through call–recall cervical
screening records.
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Among women who had not ceased screening due to age by 2016 (n = 17,602), 642 women aged
30–64 years were recorded as ceased on the call–recall system due to hysterectomy: 0.3% aged
30–39 years, 2.5% aged 40–49 years, 5.3% aged 50–59 years and 6.9% aged 60–64 years.
Natural history of human papillomavirus infection
Table 2 shows the prevalence of HPV infection at rounds 1 and 2 by age. HC2 was the primary assay
used and only HC2+ samples were further genotyped. Overall, 4% of samples tested positive by HC2
but no HRHPV was detected. These have been assumed to be HRHPV– in the analysis shown in Table 3,
which shows prevalence of HRHPV by age at round 2 among women who were HPV– at round 1, and
prevalence rates of type-specific persistence and new infection among those who were HPV+ at round 1.
The prevalence of new infection falls steeply with age in those women who were HPV– at round 1, from
19.7% at 20–24 years to 1.0% at 55–64 years. In contrast, among women who were HPV+ at round 1,
the proportion with persistence at round 2 (17.9%) shows little or no age trend. Round 2 HPV prevalence
in women who were HPV– at entry in ARTISTIC and in the POBASCAM (the Netherlands)14 and NTCC
(Italy) trials14 are shown by age in Figure 2 and by HPV type in Figure 3, in which ARTISTIC data are
restricted to the age range of the NTCC trial. The screening interval was 3 years in ARTISTIC and NTCC
and 5 years in the POBASCAM trial. Figure 2 shows remarkably similar HRHPV rates in England, Italy and
the Netherlands above the age of 33 years, but higher rates in ARTISTIC for younger women. Figure 3
shows the data by HPV genotype.
The proportion of HPV infections clearing increased by time interval to testing (Table 4). Clearance of new
HPV infections (i.e. infections that had developed in the preceding screening interval) was higher than
persisting HPV infections (i.e. those that were present at the previous screening round). Clearance of HPV
16 infection was lower than other infections and approximately 40% of new HPV 16 infections were still
persisting in women tested over 3 years.
Short-term recurrence was assessed among 405 women who were HRHPV+ at entry and who tested
HC2– less than 2 years after entry (Table 5). Of these, 27 (6.7%) women had a recurrent infection of the
same HPV type present at entry. Long-term recurrence was assessed among 415 women who were
HRHPV+ at entry and tested HC2– at least 2 years later. Of these, only five (1.2%) women had a later
recurrence or reinfection of the HPV type present at entry.
TABLE 1 The CIN3 and invasive cancer cases
Histology only
(2001–9), n (%)
Registration only
(2001–15), n (%)
Both histology and
registration, n (%) Total number
CIN3 99 (20.4) 94a (19.3) 293 (60.3) 486
Invasive cancer 11b (47.8) 12 (52.2) 23
Year of diagnosis
2001–3 61 (21.2) 7 (2.4) 220 (76.4) 288
2004–6 21 (22.8) 11 (12.0) 60 (65.2) 92
2007–9 17 (23.6) 30 (41.7) 25 (34.7) 72
2010–15 0 (0.0) 57 (100.0) 0 (0.0) 57
Total 99 (19.4) 105 (20.6) 305 (59.9) 509
a Three CIN3 were excluded owing to censoring at last cytology (2007, n= 1; 2010, n= 2).
b One invasive cancer excluded owing to censoring at ceasing screening at age 64 years (after 2010).
RESULTS
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Comparison with data from the UK primary human papillomavirus screening pilot
A UK pilot study is trialling primary HPV screening in six sites in England. Women who are HPV+ and have
borderline or worse cytology are referred to colposcopy and those with negative cytology are recalled after
12 months for repeat HPV testing and cytology.15 An immediate effect of introducing primary HPV testing
is diagnosis of prevalent CIN3+ which had been missed by previous cytology. This was seen in ARTISTIC,10
the NTCC trial16 and in a German study,17 and a much lower CIN3 rate than at entry will presumably be
seen in later screening rounds in the UK pilot study.15 Table 6 shows that the prevalence of moderate/
severe cytology among HPV+ women in ARTISTIC was similar at each age in round 1 of ARTISTIC and in
the pilot study, but in round 2 it was about three times lower and referral rates were halved. This reflects
prevalent disease that had been missed by previous cytology but was reliably detected by HPV testing.
When primary HPV testing has been rolled out nationally it may be safe to introduce a longer recall interval
for HPV+ women with borderline/mild cytology in round 2 whose previous HPV test was negative.
TABLE 2 Age-specific HRHPV prevalence at round 1 (entry) and round 2 (30–48 months later)
Age (years)
Prevalence, n (%)
Total
HRHPV+,
n (%)HPV 16/18
HPV
31/33/45/52/58
Other
HRHPV
No HRHPV
detected
(HC2+) HC2–
Round 1 (entry)
20–24 408 (15.7) 254 (9.8) 204 (7.9) 167 (6.4) 1560 (60.2) 2593 (33.4)
25–29 264 (10.2) 200 (7.7) 145 (5.6) 106 (4.1) 1874 (72.4) 2589 (23.5)
30–34 190 (5.2) 200 (5.4) 131 (3.6) 164 (4.5) 2998 (81.4) 3683 (14.2)
35–39 103 (2.6) 104 (2.6) 120 (3.1) 150 (3.8) 3462 (87.9) 3939 (8.3)
40–44 58 (1.7) 56 (1.7) 70 (2.1) 128 (3.8) 3069 (90.8) 3381 (5.4)
45–49 26 (1.0) 42 (1.6) 43 (1.6) 110 (4.1) 2496 (91.9) 2717 (4.1)
50–54 25 (1.1) 29 (1.2) 28 (1.2) 90 (3.8) 2210 (92.8) 2382 (3.4)
55–59 19 (1.0) 10 (0.5) 22 (1.1) 67 (3.4) 1853 (94.0) 1971 (2.6)
60–64 11 (0.9) 7 (0.6) 11 (0.9) 47 (3.8) 1165 (93.9) 1241 (2.3)
Total 1104 (4.5) 902 (3.7) 774 (3.2) 1029 (4.2) 20,687 (84.5) 24,496 (11.4)
Round 2 (30–48 months)
20–24 36 (9.4) 37 (9.6) 22 (5.7) 29 (7.6) 260 (67.7) 384 (24.7)
25–29 73 (8.1) 57 (6.3) 33 (3.7) 69 (7.6) 673 (74.4) 905 (18.0)
30–34 66 (4.7) 45 (3.2) 30 (2.2) 65 (4.7) 1187 (85.2) 1393 (10.1)
35–39 25 (1.3) 51 (2.5) 40 (2.0) 73 (3.6) 1819 (90.6) 2008 (5.8)
40–44 14 (0.6) 39 (1.7) 19 (0.8) 72 (3.2) 2129 (93.7) 2273 (3.2)
45–49 19 (1.0) 23 (1.2) 11 (0.6) 48 (2.5) 1846 (94.8) 1947 (2.7)
50–54 8 (0.5) 14 (0.8) 13 (0.8) 48 (2.9) 1574 (95.0) 1657 (2.1)
55–59 9 (0.6) 6 (0.4) 8 (0.5) 32 (2.1) 1464 (96.4) 1519 (1.5)
60–64 6 (0.6) 5 (0.5) 7 (0.6) 29 (2.6) 1053 (95.7) 1100 (1.6)
65–69 0 (0.0) 0 (0.0) 3 (0.7) 8 (2.0) 394 (97.3) 405 (0.7)
Total 256 (1.9) 277 (2.0) 186 (1.4) 473 (3.5) 12,399 (91.2) 13,591 (5.3)
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FIGURE 2 New infections: prevalence of HRHPV at round 2 in the ARTISTIC, NTCC (Italy) and POBASCAM
(the Netherlands) trials in women who were HRHPV– at entry.
TABLE 3 Women who were HRHPV+ at round 2 by age at round 2. Results are shown separately for those
HRHPV– at entry and those HRHPV+ at entry
Age (years)
at round 2
Infection status at entry
HRHPV– HRHPV+
Number of
women
New HRHPV at
round 2, n (%)
Number of
women
New HRHPV at
round 2, n (%)
Persisting HRHPV type
at round 2, n (%)
20–24 239 47 (19.7) 145 20 (13.8) 28 (19.3)
25–29 648 77 (11.9) 257 37 (14.4) 49 (19.1)
30–34 1119 60 (5.4) 274 21 (7.7) 60 (21.9)
35–39 1814 68 (3.8) 194 16 (8.2) 32 (16.5)
40–44 2138 48 (2.3) 135 7 (5.2) 17 (12.6)
45–49 1869 37 (2.0) 78 8 (10.3) 8 (10.3)
50–54 1602 24 (1.5) 55 0 (0.0) 11 (20.0)
55–59 1482 14 (0.9) 37 3 (8.1) 6 (16.2)
60–64 1079 12 (1.1) 21 3 (14.3) 3 (14.3)
65–69 396 1 (0.3) 9 0 (0) 2 (22.2)
All women 12,386 388 (3.1) 1205 115 (9.5) 216 (17.9)
Persistence indicates the same HRHPV type at both rounds.
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Invasive cervical cancer
Table 7 shows the 23 invasive cancers identified within the cohort between 2001 and 2015 by HPV result
and cytology at entry. The six HC2– samples were further tested using PCR-based assays and five were
found to contain HRHPV deoxyribonucleic acid (DNA) (HPV 16 in four women, HPV 51 in one woman).
Low levels of HPV 52 DNA were detected in a later sample (3 years after entry but 3 years before cancer
registration) taken from the sixth woman. The 10 prevalent cancers diagnosed within 7 months of entry
were all PCR+ with moderate or worse cytology, and nine were HC2+. Test positivity at entry for the
remaining 13 women whose cancers were diagnosed between 4 and 13 years later was 15% (2/13)
HPV39
ARTISTIC (n = 11,022 aged 24–60 years)
HRHPV prevalence (%)
POBASCAM (n = 16,671 aged 30–56 years)
NTCC (n = 7434 aged 24–60 years)
HPV16
HPV18
HPV31
HPV33
HPV35
HPV45
HPV51
HPV52
HPV56
HPV58
HPV59
HPV68
0.4 0.6 0.7 0.8 0.9 1.00.50.30.20.10.0
Trial
FIGURE 3 New infections: prevalence (%) at round 2 of each HRHPV type in the ARTISTIC, NTCC and POBASCAM
trials in women who were HRHPV– at entry.
TABLE 4 Clearance of new and persistent HRHPV infections
Infections
Proportion of infections clearing by time to next HPV test, n/N (%)
< 1 year 1–2 years 2–3 years ≥ 3 years
New HPV 16 infections 20/51 (39.2) 18/26 (69.2) 7/13 (53.9) 7/12 (58.3)
Other new infections 142/249 (57.0) 107/144 (74.3) 53/65 (81.5) 66/74 (89.2)
All new infectionsa 162/300 (54.0) 125/170 (73.5) 60/78 (76.9) 73/86 (84.9)
HPV 16: present at entry 20/94 (21.3) 12/22 (54.6) 9/21 (42.9) 7/12 (58.3)
Other infections: present at entry 91/243 (37.5) 52/104 (50.0) 44/65 (67.7) 36/48 (75.0)
All infections present at entryb 111/337 (32.9) 64/126 (50.8) 53/86 (61.6) 43/60 (71.7)
a Next HPV test following first detection of 634 HRHPV types in 504 women who did not have that HRHPV type at entry.
b Second HPV test for 609 HRHPV types detected at entry in 522 women.
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TABLE 5 The HPV type-specific recurrence following a negative HC2 test of HPV infections that were detected at entry
Recurrence
Months from HC2– test to next HPV test
0 6 12 24 36 ≥ 48
Short-term recurrence (following a HC2– test < 24 months after entry)
Number of women 26 81 122 118 29 29
Cumulative number of women 26 107 229 347 376 405
Cumulative recurrent infections (%) 2 (7.69) 7 (6.54) 14 (6.11) 21 (6.05) 22 (5.85) 27 (6.67)
Long-term recurrence (following a HC2– test 24–54 months after entry)
Number of women 11 54 81 77 175 17
Cumulative number of women 11 65 146 223 398 415
Cumulative recurrent infections (%) 0 (0.0) 0 (0.0) 1 (0.68) 1 (0.45) 5 (1.26) 5 (1.20)
TABLE 6 Cytology triage of HPV+women in the UK primary HPV screening pilot sites and ARTISTIC rounds 1 and 2 by age
Age (years) at test HPV+,a n (%)
Cytology result among HPV+ women, n (%)
Referral rate,b %Negative Borderline/mild Moderate+
Pilot sites
25–29 8231 (28.3) 5108 (62.1) 2019 (24.5) 1104 (13.4) 11.0
30–39 6127 (13.6) 4170 (68.1) 1330 (21.7) 627 (10.2) 4.5
40–49 4024 (8.0) 2951 (73.3) 822 (20.4) 251 (6.2) 2.2
50–59 1937 (6.0) 1453 (75.0) 365 (18.8) 119 (6.1) 1.5
60–64 333 (4.7) 273 (82.0) 42 (12.6) 18 (5.4) 0.9
All women 20,652 (12.6) 13,955 (67.6) 4578 (22.2) 2119 (10.3) 4.2
Round 1 ARTISTIC
25–29 716 (27.7) 374 (52.2) 245 (34.4) 96 (13.4) 13.2
30–39 1161 (15.2) 679 (58.5) 339 (29.1) 144 (12.4) 6.3
40–49 533 (8.7) 343 (64.4) 137 (25.7) 53 (9.9) 3.1
50–59 290 (6.7) 238 (82.1) 40 (13.8) 12 (4.1) 1.2
60–64 76 (6.1) 68 (89.5) 3 (3.9) 5 (6.6) 0.6
All women 2776 (12.7) 1702 (61.3) 764 (27.5) 310 (11.2) 4.9
Round 2 ARTISTIC
25–29 230 (25.6) 160 (69.6) 63 (27.4) 7 (3.0) 7.8
30–39 393 (11.6) 267 (67.9) 107 (27.2) 19 (4.8) 3.7
40–49 239 (5.7) 193 (80.8) 40 (16.7) 6 (2.5) 1.1
50–59 137 (4.3) 113 (82.5) 23 (16.8) 1 (0.7) 0.8
60–64 46 (4.2) 43 (93.5) 3 (6.5) 0 (0.0) 0.3
All women 1045 (8.2) 776 (74.3) 236 (22.6) 33 (3.2) 2.1
a HC2 assay used in ARTISTIC and either Gen-Probe Aptima® (Gen-Probe Incorp., San Diego, CA, USA), Abbott Realtime®
(Abbott Molecular, Maiden head, UK) or Roche COBAS® (Roche Molecular Diagnostics, Pleasanton, CA, USA) assays used
in the pilot sites.
b Women who are HPV+ and have abnormal cytology are immediately referred to colposcopy according to the pilot sites protocol.
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for cytology, 62% (8/13) for HC2 and 92% (12/13) for PCR. Table 8 shows that cancer is almost as
common as CIN3 in those women aged ≥ 55 years, indicating the need to focus on sensitivity for cancer
as well as CIN3 detection in a woman’s final (exit) screen. With up to 14 years of follow-up since trial
entry in 2001–3, there have so far been no cervical cancer deaths in the cohort.
Section 2: the long-term protection of a negative human papillomavirus
test and, hence, the safe screening interval at different ages
Table 9 shows cumulative CIN3+ risks in women testing HC2– at rounds 1 and 2 by age. The 10-year risks
decrease from 1.10% [95% confidence interval (CI) 0.69% to 1.77%] in women aged 20 –25 years at
entry to 0.08% (95% CI 0.03% to 0.20%) in women aged ≥ 50 years at entry. The 10-year CIN3+ risk in
all HPV– women aged 25–39 years was 0.40% (95% CI 0.28% to 0.56%) and significantly higher than
the risk in women aged ≥ 40 years at entry (0.11%, 95% CI 0.06% to 0.20%; p < 0.0001). Table 10
shows cumulative risks from round 2 in those HC2– at both time points compared with those women who
had cleared an infection present at entry. Risks were based on very small numbers, but were approximately
TABLE 7 Invasive cervical cancers identified through national registration data in 24,946 women by HPV and
cytology status at entry (follow-up to 2015)
Time from entry to cancer
registration
Cytology HC2+ HC2–
Total
Normal
n (%)
Abnormal
n (%)
PCR+
n (%)
PCR–
n (%)
PCR+
n (%)
PCR–
n (%)
0–7 months 0 10 (0.3) 9a (0.3) 0 1 (0.6) 0 10
8–47 months 0 0 0 0 0 0 0
4–13 years 11 (0.05) 2 (0.06) 8 (0.3) 0 4 (2.5) 1b (0.005) 13
Number of women 21,369 3127 2780 1029 157c 20,530 24,496
a The entry sample was HC2+ with glandular neoplasia but insufficient for further testing in a woman whose cancer was
diagnosed 4 months after entry. As the remaining 16 HC2+ samples were all PCR+ she is shown as PCR+.
b Low-level HPV52 DNA was detected in a later HC2– sample taken 3 years after entry and 3 years before cancer
registration from the only HC2–PCR– woman.
c Estimated from PapilloCheck results at round 3 (0.76% HPV+ in 4473 HC2– samples).13 Entry samples for women who
developed cancer were tested later with RLB, but PCR was not done on other HC2– entry samples.
TABLE 8 National registrations of cervical cancer and CIN3 in ARTISTIC in 2001–15 and in England in 2014
Age at registration (years)
20–29 30–39 40–49 50–59 60–69
ARTISTIC
Cervical cancer 0 7 10 4 2
CIN3 158 163 55 10 2
CIN3-to-cancer ratio ∞ 23.3 5.5 2.5 1.0
England
Cervical cancer 483 643 521 330 230
CIN3 14,458 7752 2692 848 206
CIN3-to-cancer ratio 29.9 12.1 5.2 2.6 0.9
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TABLE 9 Cumulative CIN3+ risks following a single HC2– HPV test at round 1 (n= 20,687) and at round 2 (n= 12,399) by age at test
Women who were HC2– at round 1
Age (years) at
round 1
Number (%)
of women
at baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
20–24 1563 19 3 0.19 (0.06 to 0.59) 6 0.39 (0.17 to 0.86) 17 1.10 (0.69 to 1.77)
25–29 1870 16 5 0.27 (0.11 to 0.64) 8 0.43 (0.22 to 0.86) 14 0.76 (0.45 to 1.28)
30–39 6466 20 7 0.11 (0.05 to 0.23) 12 0.19 (0.11 to 0.33) 19 0.30 (0.19 to 0.46)
40–49 5562 9 4 0.07 (0.03 to 0.19) 7 0.13 (0.06 to 0.26) 8 0.14 (0.07 to 0.29)
50–64 5226 4 2 0.04 (0.01 to 0.15) 4 0.08 (0.03 to 0.20) 4 0.08 (0.03 to 0.20)
All women (HC2–) 20,687 (84.5) 68 21 0.10 (0.07 to 0.16) 37 0.18 (0.13 to 0.25) 62 0.31 (0.24 to 0.39)
Women who were HC2– at round 2
Age (years) at
round 2
Number (%)
of women
at round 2
Number
of CIN3+
women
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
23–24 304 1 0 1 0.33 (0.05 to 2.35) 1 0.33 (0.05 to 2.35)
25–29 701 0 0 0 0
30–39 3131 9 4 0.13 (0.05 to 0.34) 5 0.16 (0.07 to 0.38) 9 0.29 (0.15 to 0.56)
40–49 3949 2 1 0.03 (0.00 to 0.18) 1 0.03 (0.00 to 0.18) 2 0.05 (0.01 to 0.20)
50–68 4314 1 1 0.02 (0.00 to 0.16) 1 0.02 (0.00 to 0.16) 1 0.02 (0.00 to 0.16)
All women (HC2–) 12,399 (91.2) 13 6 0.05 (0.02 to 0.11) 8 0.07 (0.03 to 0.13) 13 0.11 (0.06 to 0.2)
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TABLE 9 Cumulative CIN3+ risks following a single HC2– HPV test at round 1 (n= 20,687) and at round 2 (n= 12,399) by age at test (continued )
Women who were cytology negative at round 1 (concealed arm only)
Age (years) at
round 1
Number (%)
of women
at baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
20–24 489 11 4 0.82 (0.31 to 2.17) 9 1.85 (0.97 to 3.53) 11 2.27 (1.26 to 4.06)
25–29 523 9 2 0.38 (0.10 to 1.52) 4 0.77 (0.29 to 2.03) 8 1.55 (0.78 to 3.08)
30–39 1642 13 6 0.37 (0.16 to 0.81) 8 0.49 (0.25 to 0.98) 11 0.68 (0.37 to 1.22)
40–49 1340 3 0 1 0.07 (0.01 to 0.53) 2 0.15 (0.04 to 0.60)
50–64 1341 2 1 0.07 (0.01 to 0.53) 2 0.15 (0.04 to 0.60) 2 0.15 (0.04 to 0.60)
All women
(cytology negative)
5335 38 13 0.24 (0.14 to 0.42) 24 0.45 (0.30 to 0.67) 34 0.65 (0.46 to 0.90)
a In 12 years of follow-up.
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three times higher among those women who cleared an infection at entry. Presumably this is confounded
with sexual activity and, hence, risk of acquiring a new HPV infection. Figure 4 and the bottom panel of
Table 9 show a similar CIN3+ risk 10 years after a negative HPV test (0.31%, 95% CI 0.18% to 0.49% in
the revealed arm) and 3 years after a negative cytology test (0.30%, 95% CI 0.23% to 0.41% in the
concealed arm). These data support a much longer screening interval after a negative HPV test than after a
negative cytology test.
Section 3: the role of human papillomavirus typing
The increasing availability of partial genotyping allows risk-based stratification in an organised screening
programme. Four of the six sites are utilising partial typing HPV tests (Roche COBAS and Abbott Realtime
assays) in the English pilot study, which both allow identification of HPV 16 and HPV 18 infections.
Table 11 and Figure 5 show that the cumulative risk for women with HPV 16 is much higher than for
any other genotype. Women with HPV 16 constituted 22% of all HC2+ infections, but 57% of CIN3+
occurred among this group of women, giving a 10-year cumulative CIN3+ risk of 29.8% (95% CI 26.8%
to 33.0%). HPV 18 was a much less common type among ARTISTIC women, constituting 9% of all HC2+
infections (including 2% who also had HPV 16) and the 10-year cumulative risk did not differ from the
group of types including 31, 33, 45, 52 and 58. It is clear that assays that could identify these five types
in addition to HPV 16 and 18 would be beneficial for a risk-based referral strategy.
Table 12 and Figure 6 show the risks following two tests approximately 3 years apart. The 10-year cumulative
CIN3+ risk following a new HPV infection is low at 3.4% (95% CI 2.1% to 5.4%). The 10-year CIN3 risk from
round 2 was no higher in those women who were HPV+ with another type at round 1 (2.7%, 95% CI 0.9%
to 8.0%) than in those women who were HPV– at round 1 (3.6%, 95% CI 2.2% to 6.0%).
The highest risks were associated with type-specific persistent infections that, overall, conferred a 10-year
cumulative risk of 20.4% (95% CI 15.65% to 26.45%). HPV 16 again showed the highest risks and the
10-year risk following a new infection reached 7.3% (95% CI 3.7% to 14.1%), suggesting that any women
with HPV 16 detected could be referred immediately. Of the 331 women with double-positive HRHPV tests
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FIGURE 4 Cumulative CIN3+ risk (%) following a negative HPV test or normal cytology at entry.
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TABLE 10 Cumulative CIN3+ risks by combination of results at round 1 and at round 2 (30–48 months after round 1)
HPV status at
rounds 1 and 2
Number of
women at
round 2
Number
of CIN3+
women
Risk from round 2
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HC2 results (aged 20–64 years at entry)
HC2 double positive 510 54 45 8.8 (6.7 to 11.6) 49 9.6 (7.4 to 12.5) 54 10.6 (8.2 to 13.6)
HC2 negative positive 682 15 12 1.8 (1.0 to 3.1) 14 2.1 (1.2 to 3.5) 15 2.2 (1.3 to 3.6)
HC2 positive negative 1249 3 1 0.08 (0.01 to 0.57) 2 0.16 (0.04 to 0.65) 3 0.25 (0.08 to 0.76)
HC2 double negative 11,150 10 5 0.04 (0.02 to 0.11) 6 0.05 (0.02 to 0.112) 10 0.09 (0.05 to 0.17)
Aged 25–39 years at entry
HC2 positive negative 615 3 1 0.16 (0.02 to 1.15) 2 0.33 (0.08 to 1.30) 3 0.49 (0.16 to 1.52)
HC2 double negative 4019 6 3 0.07 (0.02 to 0.23) 3 0.07 (0.02 to 0.23) 6 0.15 (0.07 to 0.33)
Aged 40–64 years at entry
HC2 positive negative 410 0 0 0 0
HC2 double negative 6673 3 2 0.03 (0.01 to 0.12) 2 0.03 (0.01 to 0.12) 3 0.05 (0.02 to 0.15)
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TABLE 11 Cumulative CIN3+ risks following a single HPV test at entry by HPV genotype
Single HPV test
at round 1
Number (%)
of women at
baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HPV 16 831 (3.4) 249 219 26.4 (23.5 to 29.5) 238 28.7 (25.7 to 31.9) 247 29.8 (26.8 to 33.0)
HPV 18 273 (1.1) 36 23 8.4 (5.7 to 12.4) 32 11.7 (8.4 to 16.2) 36 13.2 (9.7 to 17.9)
HPV 31/33/45/
52/58
902 (3.7) 104 75 8.3 (6.7 to 10.3) 89 9.9 (8.1 to 12.0) 101 11.3 (9.4 to 13.5)
Other HRHPV 774 (3.2) 30 20 2.6 (1.7 to 4.0) 26 3.4 (2.3 to 4.9) 29 3.8 (2.6 to 5.4)
HC2+ non-high
riskb
1029 (4.2) 18 8 0.8 (0.4 to 1.6) 13 1.3 (0.7 to 2.2) 18 1.8 (1.1 to 2.8)
All HC2+ 3809 (15.5) 437 345 9.1 (8.2 to 10.0) 398 10.5 (9.5 to 11.5) 431 11.4 (10.4 to 12.4)
HC2– 20,687 (84.5) 68 21 0.10 (0.07 to 0.16) 37 0.18 (0.13 to 0.25) 62 0.31 (0.24 to 0.39)
Total women 24,496 (100) 505 366 435 493
a In 12 years of follow-up.
b HC2+ but no HRHPV detected, including 27 women at entry with insufficient samples for typing (in whom two CIN3+ cases were diagnosed).
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(see Table 3), 115 (35%) were positive with a new HPV type at the second test and 216 (65%) was
type-specific persistent. The proportion of new infections was highest in younger women (43% in women
in their 20s) and decreased to just 23% of double-positive infections in women aged ≥ 50 years.
Section 4: triage of human papillomavirus-positive women, particularly
the interval to retesting for human papillomavirus-positive women
Table 13 shows cumulative CIN3+ risks by HPV type and cytology at entry. Referring moderate or worse
cytology to immediate colposcopy is clearly a highly effective strategy for identifying those women at
highest risk of disease (52% by 5 years). Among HC2+ women, the 10-year cumulative CIN3+ risks in
those with negative and borderline/mild cytology were estimated to be 4.1% (95% CI 3.3% to 5.0%) and
10.3% (95% CI 8.7% to 12.2%), respectively. These risks vary by HPV genotype, and, hence, a partial
genotyping assay could identify those at highest risk (e.g. HPV 16 or 18). Table 14 is restricted to the
1116 women who were HC2+ and cytology negative and had a follow-up sample taken 30–48 months
later (round 2). The current UK protocol for HC2+ cytology-negative women is to repeat HPV and cytology
testing at 12 and 24 months and refer all those still HPV+ at 24 months. Table 14 shows these women
under a protocol of repeat testing after a 3-year recall interval. This excludes 10 CIN3+ that were diagnosed
in cytology-negative HPV+ women in the revealed arm who were diagnosed before the round 2 test, but
under a 3-year recall protocol would probably have been diagnosed at round 2. Analysis restricted to the
concealed arm would avoid this bias. Only 277 out of the 1120 women in Table 14 were in the concealed
arm and the results were consistent between the arms; therefore, they were pooled to maximise numbers.
The majority of women cleared their infection by round 2, with 72% testing HC2– and a further 7% who
remained HC2+ in whom no HRHPV was detected. A small proportion (1.3%) of women developed
moderate or worse cytology by round 2, most (9 out of 15) of whom had CIN3+ immediately diagnosed.
Out of 220 women who remained HPV+ with normal, borderline or mild cytology, 38% were infected with
a new HPV type and 62% were type-specific persistent. Among the new infections, the 10-year cumulative
CIN3+ risk remained low (3.7%, 95% CI 1.2% to 11.0%). The risks were slightly higher for those women
with borderline or mild cytology, but there was insufficient power to detect a significant difference. Further
genotyping of these samples to determine type-specific persistence would refer only those women at
highest risk of developing CIN3+ to colposcopy.
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FIGURE 5 Cumulative CIN3+ risks by HPV detection from entry (483 CIN3, 23 invasive cervical cancers in
24,500 women).
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TABLE 12 Cumulative CIN3+ risks following round 2 for women with and without type-specific persistence of HPV infection since round 1
HPV status at round 2
Number of women
at round 2 n CIN3+
Risk from round 2
2.5-year 5-year 10-year
n CIN3+ (%) 95% CI n CIN3+ (%) 95% CI n CIN3+ (%) 95% CI
Women with type-specific persistence
Persistent HPV 16 66 22 20 30.3 (20.7 to 42.9) 21 31.8 (22.1 to 44.5) 22 33.4 (23.4 to 46.1)
Persistent HPV 18 23 3 3 13.0 (4.4 to 35.2) 3 13.0 (4.4 to 35.2) 3 13.0 (4.4 to 35.2)
Persistent 31/33/45/52/58 83 15 12 14.5 (8.5 to 24.1) 13 15.7 (9.4 to 25.4) 15 18.1 (11.3 to 28.2)
Persistent other HRHPV 44 4 3 6.8 (2.3 to 19.7) 4 9.1 (3.5 to 22.4) 4 9.1 (3.5 to 22.4)
Any HRHPV type specific
persistence
216 44 38 17.6 (13.1 to 23.4) 41 19.0 (14.4 to 24.9) 44 20.4 (15.6 to 26.4)
Women without type-specific persistence
New HPV 16 109 8 7 6.4 (3.1 to 13.0) 8 7.3 (3.7 to 14.1) 8 7.3 (3.7 to 14.1)
New HPV 18 50 0 0 0.0 0 0.0 0 0.0
New 31/33/45/52/58 193 8 7 3.6 (1.8 to 7.5) 7 3.6 (1.8 to 7.5) 8 4.2 (2.1 to 8.1)
New other HRHPV 151 1 0 0.0 0 0.0 1 0.7 (0.1 to 4.8)
Any new HRHPV 503a 17 14 2.8 (1.7 to 4.7) 15 3.0 (1.8 to 4.9) 17 3.4 (2.1 to 5.4)
HC2+ but no HRHPV 473 8 5 1.1 (0.4 to 2.5) 7 1.5 (0.7 to 3.1) 8 1.7 (0.9 to 3.4)
HC2– 12,399 13 6 0.05 (0.02 to 0.11) 8 0.07 (0.03 to 0.13) 13 0.11 (0.06 to 0.19)
HC2 results ignoring genotyping
HC2 double positive 510 54 45 8.8 (6.7 to 11.6) 49 9.6 (7.4 to 12.5) 54 10.6 (8.2 to 13.6)
HC2 negative positive 682 15 12 1.8 (1.0 to 3.1) 14 2.1 (1.2 to 3.5) 15 2.2 (1.3 to 3.6)
HC2 positive negative 1249 3 1 0.08 (0.01 to 0.57) 2 0.16 (0.04 to 0.65) 3 0.25 (0.08 to 0.76)
HC2 double negative 11,150 10 5 0.04 (0.02 to 0.11) 6 0.05 (0.02 to 0.112) 10 0.09 (0.05 to 0.17)
All women 13,591 82 63 71 82
a 115 (23%) HRHPV+ at round 1.
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Tables 15 and 16 show cumulative CIN3+ risks following new and persisting HPV infections at round 2
in women with negative and borderline/mild cytology, respectively. Similar patterns are seen, with the
highest risks in women with persisting infections and in those with HPV 16 infections.
Section 5: optimal ages at starting and stopping screening
Table 17 and Figure 7 show that the cumulative CIN3+ risk 5 years after round 2 in women with
type-specific persisting infection is similar regardless of age before the age of 40 years (23.8%, 95% CI
18.2% to 30.9%), but significantly lower in women aged ≥ 40 years (6.8%, 95% CI 2.3% to 19.7%;
p = 0.02). Persistent HPV 16 infections account for 44% of the type-specific infections in those women
aged < 30 years, but only 11% among women aged ≥ 40 years.
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FIGURE 6 Cumulative CIN3+ risks following round 2 for persistent and newly acquired HPV infection (82 CIN3+ in
13,591 women).
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TABLE 13 Cumulative CIN3+ risks following a single HPV test at round 1 by HPV type and cytology
Negative cytology
at round 1
Number (%)
of women
at baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HPV 16 332 (1.6) 41 22 6.6 (4.4 to 9.9) 36 10.9 (8.0 to 14.7) 41 12.4 (9.3 to 16.5)
HPV 18 146 (0.7) 10 1 0.7 (0.1 to 4.8) 6 4.1 (1.9 to 8.9) 10 6.9 (3.8 to 12.4)
HPV 31/33/45/52/58 482 (2.3) 25 6 1.3 (0.6 to 2.8) 14 2.9 (1.7 to 4.9) 22 4.6 (3.1 to 7.0)
Other HRHPV 479 (2.2) 9 3 0.6 (0.2 to 1.9) 7 1.5 (0.7 to 3.1) 8 1.7 (0.8 to 3.3)
HC2+ non-high riskb 784 (3.7) 9 1 0.1 (0.02 to 0.90) 5 0.6 (0.3 to 1.5) 9 1.2 (0.6 to 2.2)
All HC2+ 2223 (10.4) 94 33 1.5 (1.1 to 2.1) 68 3.1 (2.4 to 3.9) 90 4.1 (3.3 to 5.0)
HC2– 19,146 (89.6) 53 11 0.06 (0.03 to 0.10) 25 0.13 (0.09 to 0.19) 48 0.26 (0.19 to 0.34)
All women with
negative cytology
21,369 (100) 147 44 93 138
Borderline/mild
cytology at round 1
Number (%)
of women
at baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HPV 16 283 (10.6) 65 54 19.1 (15.0 to 24.0) 59 20.9 (16.6 to 26.1) 63 22.3 (17.9 to 27.6)
HPV 18 93 (3.5) 10 7 7.5 (3.7 to 15.1) 10 10.8 (5.9 to 19.1) 10 10.8 (6.0 to 19.1)
HPV 31/33/45/52/58 309 (11.6) 31 24 7.8 (5.3 to 11.4) 29 9.4 (6.6 to 13.2) 31 10.1 (7.2 to 14.0)
Other HRHPV 259 (9.7) 10 7 2.7 (1.3 to 5.6) 9 3.5 (1.8 to 6.6) 10 3.9 (2.1 to 7.1)
HC2+ non-high riskb 226 (8.5) 6 4 1.8 (0.7 to 4.7) 5 2.2 (0.1 to 5.2) 6 2.7 (1.2 to 5.8)
All HC2+ 1170 (43.9) 122 96 8.2 (6.8 to 9.9) 112 9.6 (8.0 to 11.4) 120 10.3 (8.7 to 12.2)
HC2– 1495 (56.1) 10 6 0.4 (0.2 to 0.9) 7 0.5 (0.2 to 1.0) 9 0.6 (0.3 to 1.2)
All women with
borderline/mild
cytology
2665 (100) 132 102 119 129
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TABLE 13 Cumulative CIN3+ risks following a single HPV test at round 1 by HPV type and cytology (continued )
Moderate/severe
cytology at round 1
Number (%)
of women
at baseline
Number
of CIN3+
womena
Risk from round 1
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HPV 16 216 (46.8) 143 143 66.2 (59.9 to 72.4) 143 66.2 (59.9 to 72.4) 143 66.2 (59.9 to 72.4)
HPV 18 34 (7.4) 16 15 44.1 (29.4 to 62.2) 16 47.1 (32.1 to 64.9) 16 47.1 (32.1 to 64.9)
HPV 31/33/45/52/58 111 (24.0) 48 45 40.5 (32.1 to 58.3) 46 41.4 (32.9 to 51.2) 48 43.2 (34.6 to 53.0)
Other HRHPV 36 (7.8) 11 10 27.8 (16.0 to 45.5) 10 27.8 (16.0 to 45.5) 11 30.8 (18.4 to 48.7)
HC2+ non-high riskb 19 (4.1) 3 3 15.8 (5.4 to 41.4) 3 15.8 (5.4 to 41.4) 3 15.8 (5.4 to 41.4)
All HC2+ 416 (90.0) 221 216 51.9 (47.2 to 56.8) 218 52.4 (47.7 to 57.3) 221 53.2 (48.4 to 58.0)
HC2– 46 (10.0) 5 4 8.7 (3.4 to 21.5) 5 10.9 (4.7 to 24.2) 5 10.9 (4.7 to 24.2)
All women with
moderate/severe
cytology
462 (100) 226 220 223 226
a In 12 years of follow-up.
b HC2+ but no HRHPV detected.
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TABLE 14 Cumulative CIN3+ risks following round 2 in women who were HC2+ with negative cytology at entry (n= 1120) by HPV status at round 1 and round 2
Women who were HC2+ and cytology negative entry
HPV status and
cytology at round 2
Number (%)
of women
at round 2
Number
of CIN3+
women
Risk from round 2
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
HC2– 806 (72.0) 2 0 0 1 0.13 (0.02 to 0.90) 2 0.26 (0.06 to 1.03)
HC2+ but no high
risk detected
79 (7.1) 5 4 5.1 (1.9 to 12.9) 5 6.3 (2.7 to 14.5) 5 6.3 (2.7 to 14.5)
HRHPV+ normal
cytology
158 (14.1) 14 9 5.7 (3.0 to 10.7) 11 7.0 (3.9 to 12.2) 14 8.9 (5.4 to 14.5)
Persistent HRHPV 97 13 9 9.3 (4.9 to 17.1) 11 11.3 (6.5 to 19.5) 13 13.4 (8.0 to 22.0)
New HRHPV 61 1 0 0.0 0 0.0 1 1.7 (0.2 to 11.3)
HRHPV+ borderline/
mild cytology
62 (5.5) 10 8 12.9 (6.7 to 24.2) 9 14.5 (7.8 to 26.0) 10 16.2 (9.0 to 28.0)
Persistent HRHPV 40 8 7 17.5 (8.8 to 33.2) 8 20.0 (10.5 to 36.0) 8 20.0 (10.5 to 36.0)
New HRHPV 22 2 1 4.6 (0.7 to 28.1) 1 4.6 (0.7 to 28.1) 2 9.1 (2.4 to 31.7)
HRHPV+ normal/
borderline/mild
cytology
220 24
Persistent HRHPV 137 21 16 11.7 (7.3 to 18.4) 19 13.9 (9.1 to 20.9) 21 15.3 (10.3 to 22.6)
New HRHPV 83 3 1 1.2 (0.2 to 8.3) 1 1.2 (0.2 to 8.3) 3 3.7 (1.2 to 11.0)
HRHPV+ moderate/
severe cytology
15 (1.3) 9 9 60.0 (37.2 to 83.5) 9 60.0 (37.2 to 83.5)
Totala 1120 (100) 40 30 34 40
a Ten further CIN3+ women were diagnosed before round 2 in cytology-negative HPV+ women in the revealed arm (see Section 4: triage of human papillomavirus-positive women,
particularly the interval to retesting for human papillomavirus-positive women).
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TABLE 15 Cumulative CIN3+ risks following round 2 in women with negative cytology at round 2 by HPV status at round 1 and round 2
HPV status at round 2
(negative cytology)
Number
of women
at round 2
Number
of CIN3+
women
Risk from round 2
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Women with type-specific persistence
Persistent HPV 16 41 9 7 17.1 (8.5 to 32.5) 8 19.5 (10.3 to 35.3) 9 22.0 (12.1 to 38.1)
Persistent HPV 18 13 1 1 7.7 (1.1 to 43.4) 1 7.7 (1.1 to 43.4) 1 7.7 (1.1 to 43.4)
Persistent 31/33/45/52/58 54 7 4 7.4 (2.9 to 18.5) 5 9.3 (4.0 to 20.8) 7 13.0 (6.4 to 25.3)
Persistent other HRHPV 26 0 0 0.0 0 0.0 0 0.0
Any HRHPV type specific
persistence
134 17 12 9.0 (5.2 to 15.2) 14 10.5 (6.3 to 17.0) 17 12.7 (8.1 to 19.7)
Women without type-specific persistence
New HPV 16 61 2 1 1.6 (0.2 to 11.1) 2 3.3 (0.8 to 12.5) 2 3.3 (0.8 to 12.5)
New HPV 18 32 0 0 0.0 0 0.0 0 0.0
New 31/33/45/52/58 143 3 2 1.4 (0.4 to 5.5) 2 1.4 (0.4 to 5.5) 3 2.1 (0.7 to 6.4)
New other HRHPV 114 0 0 0.0 0 0.0 0 0.0
Any new HRHPV 350a 5 3 0.9 (0.3 to 2.6) 4 1.1 (0.4 to 3.0) 5 1.4 (0.6 to 3.4)
HC2+ but no HRHPV 383 5 3 0.8 (0.3 to 2.4) 4 1.1 (0.4 to 2.8) 5 1.3 (0.6 to 3.2)
HC2– 12,028 12 5 0.04 (0.02 to 0.10) 7 0.06 (0.03 to 0.12) 12 0.10 (0.06 to 0.18)
HC2 results ignoring genotyping
HC2 double positive 331 21 15 4.5 (2.8 to 7.4) 17 5.1 (3.2 to 8.1) 21 6.4 (4.2 to 9.6)
HC2 negative positive 536 6 3 0.6 (0.2 to 1.7) 5 0.9 (0.4 to 2.2) 6 1.1 (0.5 to 2.5)
HC2 positive negative 1166 2 0 0.0 1 0.09 (0.01 to 0.62) 2 0.18 (0.04 to 0.71)
HC2 double negative 10,862 10 5 0.05 (0.02 to 0.11) 6 0.06 (0.02 to 0.12) 10 0.09 (0.05 to 0.18)
All women 12,895 39 23 29 39
a Eighty-one (23%) HRHPV+ women at round 1.
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TABLE 16 Cumulative CIN3+ risks following round 2 in women with borderline or mild cytology at round 2 by HPV status at round 1 and round 2
HPV status at round 2
(negative cytology)
Number
of women
at round 2
Number
of CIN3+
women
Risk from round 2
2.5-year 5-year 10-year
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Number of CIN3+
women (%) 95% CI
Women with type-specific persistence
Persistent HPV 16 13 7 7 53.9 (30.4 to 80.8) 7 53.9 (30.4 to 80.8) 7 53.9 (30.4 to 80.8)
Persistent HPV 18 8 2 2 25.0 (6.9 to 68.5) 2 25.0 (6.9 to 68.5) 2 25.0 (6.9 to 68.5)
Persistent 31/33/45/52/58 22 3 3 13.6 (4.6 to 36.6) 3 13.6 (4.6 to 36.6) 3 13.6 (4.6 to 36.6)
Persistent other HRHPV 16 2 1 6.3 (0.9 to 36.8) 2 12.5 (3.3 to 41.4) 2 12.5 (3.3 to 41.4)
Any HRHPV type specific
persistence
59 14 13 22.0 (13.4 to 34.9) 14 23.7 (14.8 to 36.8) 14 23.7 (14.8 to 36.8)
Women without type-specific persistence
New HPV 16 42 4 4 9.5 (3.7 to 23.4) 4 9.5 (3.7 to 23.4) 4 9.5 (3.7 to 23.4)
New HPV 18 17 0 0 0.0 0 0.0 0 0.0
New 31/33/45/52/58 43 3 3 7.0 (2.3 to 20.1) 3 7.0 (2.3 to 20.1) 3 7.0 (2.3 to 20.1)
New other HRHPV 35 1 0 0.0 0 0.0 1 2.9 (0.4 to 18.6)
Any new HRHPV 137a 8 7 5.1 (2.5 to 10.4) 7 5.1 (2.5 to 10.4) 8 5.9 (3.0 to 11.4)
HC2+ but no HRHPV 79 2 1 1.3 (0.2 to 8.7) 2 2.6 (0.6 to 9.8) 2 2.6 (0.6 to 9.8)
HC2– 304 1 1 0.3 (0.05 to 2.3) 1 0.3 (0.05 to 2.3) 1 0.3 (0.05 to 2.3)
HC2 results ignoring genotyping
HC2 double positive 140 18 15 10.7 (6.6 to 17.1) 17 12.1 (7.7 to 18.8) 18 12.9 (8.3 to 19.7)
HC2 negative positive 135 6 6 4.5 (2.3 to 10.7) 6 4.5 (2.3 to 10.7) 6 4.5 (2.3 to 10.7)
HC2 positive negative 63 1 1 1.6 (0.2 to 10.7) 1 1.6 (0.2 to 10.7) 1 1.6 (0.2 to 10.7)
HC2 double negative 241 0 0 0.0 0 0.0 0 0.0
All women 579 25 22 24 25
a Twenty-seven (20%) HRHPV+ women at round 1.
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TABLE 17 Cumulative CIN3+ risks following round 2 by age in women with type-specific HPV persistence
HPV status at round 2
(negative cytology)
n at
round 2 n CIN3+
Risk from round 2
2.5-year 5-year 10-year
n CIN3+ (%) 95% CI n CIN3+ (%) 95% CI n CIN3+ (%) 95% CI
23–24
Persistent HPV 16 14 5 5 35.7 (16.7 to 65.7) 5 35.7 (16.7 to 65.7) 5 35.7 (16.7 to 65.7)
Persistent other high-risk type 18 3 2 11.1 (2.9 to 37.6) 2 11.1 (2.9 to 37.6) 3 16.7 (5.7 to 43.2)
25–29
Persistent HPV 16 25 8 6 24.0 (11.6 to 45.8) 7 28.0 (14.5 to 49.9) 8 32.0 (17.5 to 53.9)
Persistent other high-risk type 31 4 4 12.9 (5.1 to 30.8) 4 12.9 (5.1 to 30.8) 4 12.9 (5.1 to 30.8)
30–34
Persistent HPV 16 16 8 8 50.0 (29.0 to 75.5) 8 50.0 (29.0 to 75.5) 8 50.0 (29.0 to 75.5)
Persistent other high-risk type 37 6 4 10.8 (4.2 to 26.3) 5 13.5 (5.9 to 29.5) 6 16.2 (7.6 to 32.6)
35–39
Persistent HPV 16 6 1 1 16.7 (2.5 to 72.7) 1 16.7 (2.5 to 72.7) 1 16.7 (2.5 to 72.7)
Persistent other high-risk type 25 6 5 20.0 (8.9 to 41.6) 6 24.0 (11.6 to 45.8) 6 24.0 (11.6 to 45.8)
≥ 40
Persistent HPV 16 5 0 0 0 0
Persistent other high-risk type 39 3 3 7.7 (2.6 to 22.0) 3 7.7 (2.6 to 22.0) 3 7.7 (2.6 to 22.0)
All women
Persistent HPV 16 66 22 20 30.3 (20.7 to 42.9) 21 31.8 (22.1 to 44.5) 22 33.4 (23.4 to 46.1)
Persistent other high-risk type 150 22 18 12.0 (7.7 to 18.4) 20 13.3 (8.8 to 19.9) 22 14.7 (9.9 to 21.5)
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FIGURE 7 Cumulative CIN3+ risks following round 2 by age in women with type-specific persistence of any HRHPV.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
Chapter 6 Discussion
Risk-based screening and cancer prevention
The UK National Screening Programme will adopt HPV screening and triage protocols that strike an
acceptable balance between cancer risk and the cost and patient inconvenience of excessive screening
and referral rates and unnecessary treatment. Acknowledging that there is no such thing as zero risk,
Castle et al.18 proposed a risk-based strategy for cervical screening based on widely accepted practice, and
suggested that women should be returned to routine screening if they have a < 2% CIN3+ risk, recalled
earlier than the routine screening interval if they have a 2–10% risk, and referred to immediate colposcopy
if they have a > 10% risk. These specific cut-off points may be considered arbitrary and do not consider
the relationship between CIN3 and cancer risk. The aim of screening is to prevent invasive cancer and not
CIN3; therefore, the acceptable cumulative CIN3+ risk when a woman is next screened depends on the
ratio of cancer risk to CIN3 risk at the next screen. This ratio depends mainly on the delay between time of
development of CIN3 during the screening interval and its treatment when it is detected at the next HPV
test or after subsequent triage processes.
Many CIN3 cases develop soon after HPV acquisition and most develop within a few years.19 Therefore,
the CIN3 incidence rate in women who were HPV– at their last test is approximately proportional to their
age-specific incidence rate of new HPV infection (with a lag of a year or two), and, hence, proportional to
the overall population HPV prevalence (Figure 8), as most prevalent infections are newly acquired and
transient even in older women (see Table 3).
The cumulative CIN3 risk at next screen is also roughly proportional to the screening interval (Figure 9).
The cervical cancer incidence rate in women with untreated CIN3 appears to be fairly constant at about 1%
per year, independent of age,1 so the cancer risk at next screen should be roughly proportional to the square
of the screening interval. In unscreened populations with fairly constant HPV infection rates up to middle age,
cervical cancer incidence should therefore rise linearly from age at first intercourse. From 10 to 30 years after
first intercourse, the observed quadratic relationship corresponds closely to a linear increase with a diagnostic
lag of 7.5 years.20 In primary screening, women who test HPV– acquire new infections and develop resulting
CIN3 throughout the interval to next test. In contrast, in the further interval before retesting when HPV+
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FIGURE 8 Age-specific HRHPV prevalence at round 2 by age at round 2 overall and in women who were HRHPV–
at round 1, and cumulative 10-year CIN3+ risk by age at round 1 in women who were HC2– at round 1. (HRHPV
prevalence rates at round 2 by age at round 1 in women who were HRHPV– at round 1 in 5-year age groups from
20–24 years to 55–59 years were 14.7%, 8.1%, 3.6%, 2.9%, 2.2%, 1.5%, 1.5% and 0.8%.)
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women are being triaged, most CIN3 lesions will have developed long before or soon after their positive HPV
test. Therefore, some cancers will be present at the screening visit when HPV is detected, and the cancer risk
will further increase at a roughly constant rate throughout the triage process. This simplified and speculative
model ignores several relevant factors, including the lag from HPV acquisition to CIN3 development and the
rate of progression to detectable cancer, but it illustrates the weakness of screening and triage protocols based
only on CIN3+ risk. An undefined model of cancer risk underlies the focus on CIN3 that informs cervical
screening and triage protocols. An explicit model based on epidemiological knowledge should perhaps be
developed and refined as an alternative basis for cost–benefit evaluation of the details of HPV screening
and triage protocols, as it is unlikely that their effects on cancer incidence can be observed directly. Even
the simple comparison of HPV testing against cytology required the pooled results of trials with a total of
176,000 randomised women to detect the effect on cancer incidence.6
The long-term protection of a negative human papillomavirus test and,
hence, the safe screening interval at different ages
The 10-year CIN3+ rate among women who were HPV– at entry to ARTISTIC is only 0.1% in those aged
≥ 40 years, suggesting that screening intervals for HPV– women aged 40–49 years might be extended even
further than the 6 years previously suggested.4 Our data are consistent with the long-term risks reported
from women participating in the POBASCAM trial in the Netherlands that has led to the recommendation
for the Dutch HPV screening programme to adopt a 10-year screening interval in women aged ≥ 40 years.21
Many HPV– women have had an earlier infection, so this very low long-term risk after a single negative HPV
test suggests that a HPV infection that has become undetectable rarely recurs and then progresses to CIN3.
Frequent HPV testing, therefore, greatly increases the number of transient infections that are detected
without increasing sensitivity for CIN3 detection.
As noted above, if most CIN3 cases (and a large proportion of CIN2 cases) persist, then their prevalence
will increase almost linearly with increasing screening interval. This was seen in routinely screened women
in Manchester in the 1990s, in whom CIN3 prevalence increased almost linearly with longer intervals since
last normal cytology.22 Age-standardised CIN2+ prevalence in ARTISTIC shows this pattern at round 2
(Figure 9), with an annual increase of about 0.2% per year since entry in women with a cytologically
normal entry test. Figure 9 shows that CIN2+ prevalence at entry increased at a similar rate with increasing
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interval from the previous normal cytology to entry, with the addition of about 1.2% reflecting the CIN2+
prevalence missed by previous screening rounds that was detected at entry to ARTISTIC.
The role of human papillomavirus typing
The HPV+ women with borderline/mild cytology as well as those with negative cytology might be further
triaged by HPV type to identify those who can be recalled later. A HPV test that identifies HPV types 16, 18
and 31/33/45/52/58 would enable this moderate-risk subgroup, which constitutes 58.4% of HPV+ women
with borderline/mild cytology, to be referred immediately or followed up within (say) 1 year. See Table 13,
which shows the 5-year CIN3+ risks of 10.9%, 4.1% and 2.9% with negative cytology, and 20.9%, 10.8%
and 9.4% with borderline/mild cytology. Borderline/mild cytology with other HRHPV types (35, 39, 51,
59 and 68) has a 5-year CIN3+ risk of 3.5% and might be recalled 3 years later for a repeat HPV test.
Immediate referral or early retesting of women with HPV 16 was recently recommended in the Netherlands23
and proposed more than 10 years ago in the USA,24 but the cost–benefit balance of more complex triage
protocols based on full HPV typing following cytology triage deserves further consideration, particularly for
vaccinated women. Table 13 shows that most of the CIN3+ risk in HPV+ women with abnormal cytology is
present at, or soon after, HPV detection and increases by about only 2% from 2.5 to 10 years irrespective
of cytology.
Triage and referral policy in relation to primary screening interval
Figure 9 confirms that the marked reduction from round 1 to round 2 in the proportion of HC2+ women
aged ≥ 25 years who had moderate+ cytology (11.2% and 3.2%, respectively; see Table 6) reflects the
elimination of long-standing high-grade disease that had been missed at previous routine cytology. The
round 1 results, thus, represent what might be seen in primary HPV testing with a very long screening
interval, whereas round 2 shows results after an interval of about 3 years. However, the overall CIN3 risks
in HRHPV+ women were almost the same after stratifying by cytology, with 5-year CIN3 risks for normal,
borderline/mild and moderate+ cytology of 3.1%, 9.5% and 52.4%, respectively, in round 1, and 2.5%,
8.4% and 44.7%, respectively, in round 2. This suggests that recall policy following cytology triage of
HPV+ women need not depend on the primary screening interval.
Triage and referral policy in relation to type-specific human
papillomavirus persistence
Table 12 shows that the 10-year CIN3 risk for women with a new HPV type at round 2 was only 3.4%
(95% CI 2.1% to 5.4%). The risk was no higher in those whose HPV infection at round 1 had cleared
(2.7%, 95% CI 0.9% to 8.0%) than in those who were HPV– at round 1 (3.6%, 95% CI 2.2% to 6.0%).
In contrast, the 10-year CIN3 risk in women with type-specific persistence at round 2 is six times greater
than for a new infection of the same type. Among 331 women with HRHPV at both rounds, 58% had the
same type (10-year CIN3 risk 20.4%, 95% CI 15.6% to 26.4%). The 10-year CIN3 risk in the remaining
42% who had cleared the original type and acquired a new type was only 2.7%, so these women could
safely be recalled 3 years later when most of their infections will have cleared. This large difference in risk
(p < 0.0001), and, hence, the potential efficiency of further triage, is diluted with HPV tests that do not
identify all 13 high-risk types. The price of different HPV tests and the disadvantages of more complex
triage and referral protocols will determine whether or not the advantages of full HPV typing outweigh
the costs.
A triage protocol in which women are recalled repeatedly until their CIN3 risk exceeds (say) 10% implies a
cycle of repeated testing that ends only in HPV clearance or referral, and some limit must be set to detect
and treat occult CIN3 that has regressed cytologically. A HPV infection that has persisted for 5 years should
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perhaps be referred for random cervical biopsy. In a prospective study in the Netherlands, six out of the
eight women with untreated CIN who regressed to normal cytology and colposcopy but remained HRHPV+
over several years had occult CIN3 detected by random biopsy.25
We excluded women with any recorded histology in calculating HPV clearance rates, as biopsy can induce
clearance.26 This might lead to an overestimate of clearance but, as the clearance rates for new and
persistent HRHPV infections shown in Table 4 are similar to those reported by Nobbenhuis et al.27
in women followed up without intervention, any bias seems to be small.
Triage of human papillomavirus-positive women
If the screening interval is increased, the time between appearance and diagnosis of CIN3 and, hence, the
risk of progression to cancer will also increase, so the triage protocol must minimise the delay in referring
those at highest risk to colposcopy. Nonetheless, the evidence from round 1 of ARTISTIC (see Table 13)
indicates that the triage protocol being piloted in England could be too conservative, at least for HPV+
women with negative cytology. The risk of developing CIN3 within 5 years in HPV+ women is 52.4%
for moderate/severe cytology, 9.6% for borderline/mild cytology and only 3.1% for normal cytology
(see Table 13). The suggestion that a CIN3+ risk of about 10% is a reasonable threshold for immediate
colposcopy18,28 would, therefore, imply rapid referral for HPV+ women with any abnormal cytology except
perhaps the minority of women with borderline/mild cytology who have genotypes with the lowest
associated risks. The minimal increase in the risk of developing cancer by retesting women with borderline/
mild cytology rather than referring them directly to colposcopy has always been accepted, and it is not
clear that this risk/benefit balance should be abandoned when they are found to have HPV. In round 1 of
ARTISTIC, the proportion of HPV+ women with moderate + cytology was 12% below age 50 years and at
age 50 years or older. By round 2 of ARTISTIC, only 5% of HPV+ women aged < 50 years and 1% of
women aged ≥ 50 years had moderate/severe cytology. The majority of HPV+ women in a population
regularly screened by HPV testing will, thus, have negative or borderline/mild cytology.
Triage: women with normal cytology
Of the women who were HC2+ with normal cytology at entry to ARTISTIC, 72% had cleared their HPV
infection within 3 years (see Table 14). Only 1.3% (15 out of 1116) of women had moderate or worse
cytology by round 2 (of whom, nine were diagnosed with CIN3). Fourteen per cent of women remained
HPV+ with normal cytology, but approximately 60% of these (97 out of 158) had type persistent HPV and
approximately 40% (61 out of 158) had new HPV types. The subsequent elevated cumulative risk was
among those with type-specific infections. This also applied to those with borderline/mild cytology at the
follow-up, but this was based on small numbers. This implies that the current policy in the pilot sites
(repeat testing after 1 year and referral to colposcopy after 2 years if women are still HPV+ with normal
cytology) is referring a large proportion of women to unnecessary testing and colposcopy. Recall after 2 or
3 years then referring only those developing moderate+ cytology and those with type-specific persistence
may be a better strategy.
Triage: women with borderline/mild cytology
Among HPV+ 24- to 64-year-old women presenting with borderline/mild cytology at entry, 29% had
cleared their HPV infection within 1 year and an additional 19% remained HPV+ but became cytologically
normal. Those with HPV 16 with 5-year CIN3+ risk of 20.5% should clearly be referred immediately, but
inviting all HPV+ women with borderline or mild cytology to return for a repeat test at 1 year would
substantially reduce immediate referrals and could be a better strategy.
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Ages at starting and stopping screening
Stopping screening
The effect on long-term CIN3+ risk of stopping screening in women who are HPV– at various ages can be
inferred from Table 10. For example, the 10-year CIN3+ risk in HPV– women aged ≥ 50 years is only 0.1%.
Their risk of acquiring HPV is an order of magnitude lower than for women aged 20–24 years (see Table 3),
and there is plausible epidemiological evidence that HPV infection in middle age confers little lifetime risk of
cervical cancer.20 Conversely, the case for a further test at least 10 years later is that their lifetime cancer risk
could also be of the order of 1 per 1000 and possibly higher. The sharp decline with increasing age in the
CIN3-to-cancer ratio in ARTISTIC (see Table 8), and the observation that CIN3 that remains detectable by
HPV testing and random biopsy can regress to become cytologically and colposcopically undetectable25
suggests that their CIN3 risk may be underestimated. A quirk of the current screening protocol is that a
woman’s age at her final test ranges from 60 to 64 years because the final invitation is 5 years after her
previous test unless this was at age 60 years or older. One final test at the age of 65 years could be offered
to all women who were HPV– at the age of 50 years. Whatever the age at stopping, the final HPV test might
require a more sensitive test than at younger ages. Five out of the six women in ARTISTIC who developed
invasive cervical cancer after a negative HC2 entry test were found to be HRHPV+ when the stored entry
sample was retested by PCR. Alternatively, HPV and cytology cotesting might be considered at a woman’s
final test. The one woman in ARTISTIC and all three in the POBASCAM trial21 who developed invasive cancer
within 4 years of a HPV– entry test were cytologically abnormal at entry.
Age at starting screening
The natural history of HPV infection, persistence and progression to CIN3 is similar at all ages from
20 years to about 45 years, after which the CIN3 rate in HPV+ women falls (see Figure 7) and cervical cancer
incidence in unscreened populations shows a sharp inflection.20 Therefore, the age at which screening begins
(currently 25 years) might be reconsidered when HPV testing is introduced. Owing to this, we have outlined
some of the effects of beginning HPV screening at (say) age 22 years to illustrate the issues involved. Screening
after age 25 years reduces cervical cancer incidence, particularly for more advanced disease;2 therefore, earlier
screening would presumably achieve some reduction in the rising cancer incidence in young women. The
effect on referrals to colposcopy would depend on whether immediate referral was restricted to women with
moderate or severe cytology, and on the recall interval for HPV+ women with normal, borderline or mild
cytology. Almost 40% of women aged 20–24 years were HC2+ at entry to ARTISTIC, but only 4.2% had
moderate or severe cytology.3 A second test at age 25 years for those who were HPV+ at age 22 years would
enable type-specific persistence to be identified and triaged. As discussed above, the CIN3+ risk is much lower
in those with a new HPV infection; therefore, they could safely be recalled 3 years later, when most infections
will have cleared, except perhaps those with HPV 16 (see Table 12).
Study limitations
The effect of cervical sampling and biopsy on human papillomavirus clearance
A potential bias in the observed 10-year cumulative CIN3+ rates in HPV– women is the possibility that
intervening screening, biopsy and treatment could have induced clearance of subsequent HPV infections
and prevented progression to CIN3.26
Variation in cytology practice
ARTISTIC recruited from 127 centres spread throughout the Greater Manchester area and cytology was
performed in two laboratories where the staff were retrained ahead of the national roll-out of LBC,
which improved the sensitivity of our cytology,10 as this varies between laboratories. The HC2 test used
in ARTISTIC has largely been replaced for use in the NHS by modern PCR-based assays. We do not
know how these assays would have performed, particularly in detecting HPV among women who tested
HC2– at entry but subsequently developed invasive cervical cancer (see Table 7). Despite these potential
issues, we have shown similarities between the first round of ARTISTIC and the national pilot study
(see Table 6) and believe the results to be generalisable to the British population.
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Hybrid capture 2 test sensitivity
Table 2 shows that about 4% of samples from women aged ≥ 25 years who tested positive for HPV by
HC2 showed no HRHPV on genotyping. These constituted over half of HC2+ results in women aged
≥ 50 years. A total of 40% of these women had a RLU of between 1 and 2 pg/μl, indicating that most are
probably false positives.11 (The definition of HC2 test positivity is a RLU of ≥ 1 pg/μl.) Our conclusions are
unlikely to have been much affected by ignoring these women who were HC2+ but negative for the
13 high-risk target types (4.2% of all women in round 1 and 3.5% in round 2; see Table 2). Their 10-year
CIN3 rate was 1.8% (3.0% in those with low-risk HPV types and 0.8% in those negative for all 27 HPV
types identified by the linear array), and their inclusion in the HC2– group would increase the 10-year
CIN3+ risk in HC2– women from 0.31% to 0.37%. Low-risk HPV types occasionally cause high-grade
neoplasia but by definition are not associated with invasive cancer risk, so the proportion of high-grade
CIN cases that are missed by HRHPV testing is not an indication of inadequate sensitivity. Modern
PCR-based HRHPV tests may have slightly better sensitivity with respect to cancer than the HC2 test.
Human papillomavirus-negative cancers
The small proportion of cervical cancers that do not contain HPV DNA will be missed by any HPV-based
primary test. Only 0.3% were HPV– in an international series of cancer biopsies with stringent criteria for
diagnosis and PCR adequacy and separate PCR assays for each high-risk type.29 A more relevant estimate
for the practical purpose of improving routine screening is the proportion of cancers in which HPV cannot
be detected in recent cervical samples. None of the latest available samples before diagnosis from the
23 cancers in this cohort was HPV– on retesting, but Table 7 shows that the entry sample was HC2
negative but HPV positive by PCR in 5 (22%). Larger numbers tested by standard modern assays will
provide a more precise estimate of this important index of sensitivity.
Further research
The National Institute for Health Research has funded a further extension, under which follow-up for CIN2
diagnoses (which are managed clinically in the same way as CIN3 but are not recorded centrally) will be
updated through local histology laboratories. The sample bank, augmented by further samples from
women in the cohort who are screened between 2018 and 2022, will be used to retest samples from
women who develop CIN3 or cancer and matched controls. Interim results for CIN2+ as well as CIN3+ will
be provided to the NSC in order to inform its recommendations on screening intervals for HPV– women
and triage protocols following HPV detection. The same data would be available in the future from
national routine screening records if these were linked to histology records to capture CIN2 diagnoses as
well as to national cancer registration. The establishment of a larger national bank of samples from
routinely screened women would provide much larger numbers of samples from women who will develop
cervical cancer for retesting by more sensitive PCR and with alternative screening or triage assays such as
DNA methylation.
Conclusions
A screening interval of up to 10 years following a negative HPV test might be considered for women aged
≥ 40 years and perhaps for younger women following a negative HPV test. Immediate referral of all HPV+
women with mildly abnormal cytology, as adopted in the English pilot study of primary HPV screening,
may not be essential and recall intervals of 1 year for high-risk subgroups and 3 years for the remainder
could be considered. The risk is largely confined to women with a persisting type-specific HPV and a
10-year interval will identify them efficiently. The possibility of a small increase in risk of progression to
invasive cancer between screening rounds and perhaps some increase in the proportion of women who
fail to attend regularly must be weighed against the advantages for patients and reduction of NHS costs
with longer screening intervals.
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Routine HPV testing and follow-up to HPV clearance will divide the population into the low-risk HPV–
majority and those with type-specific persistent HPV infection among whom virtually all cervical cancers will
arise. Those whose infections do not disappear after repeated testing may consider curative treatment
irrespective of cytological or colposcopic findings, particularly when they reach the age at which routine
screening ends.
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